AGM/Trading Update

Deltex Medical Group PLC
03 May 2006



                  Deltex Medical Group plc ('Deltex Medical' / 'Company')

                     Results of Annual General Meeting/Trading Update

               Placing of 2,400,000 New Ordinary shares at 20p per share


3 May 2006:  Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the
AIM listed haemodynamic monitoring company today held its Annual General
Meeting.  All resolutions put to shareholders at the meeting were passed.  The
following is the text of a statement made at the meeting by the Company's
chairman, Nigel Keen.


'Progress in the first four months of 2006 indicates that Deltex Medical is
continuing to establish haemodynamic optimisation, using its CardioQTM   blood
flow monitor, as a standard of care for patients undergoing moderate and major
surgery and for those in intensive care.


In our largest market, the UK, sales of our single patient disposable probes
have continued to grow.  April was the eighteenth consecutive month when the
value of probe sales exceeded that in the corresponding month twelve months
earlier.  UK probe sales in March were the highest ever achieved in a single
month; previously the Company had achieved all time record months in both
December 2005 and August 2005.


This growth reflects increased routine usage in both operating theatres and in
intensive care units.  In operating theatres the CardioQ is the only
haemodynamic monitoring system proven in repeated, randomised, controlled trials
to reduce complications associated with major surgery and shorten length of
hospital stay.  In intensive care units the CardioQ's unique ability to identify
changes in intravascular blood flow as soon as they happen has maintained its
position as the UK's monitor of choice.


Our continuing solid growth in the UK has been achieved despite the UK NHS's
financing difficulties.  As hospitals start to look for new ways to reduce costs
while improving quality of care, the CardioQ's proven ability to both save lives
and save money is making it an ever more attractive use of scarce funds.  To
date we have sold 24 CardioQ monitors to NHS hospitals, compared to 34 in the
whole of 2005.  While it is too early to tell if this marks a change in trend,
it is particularly encouraging that five hospitals have so far this year each
bought three or four CardioQ monitors and are in the process of implementing the
CardioQ as a standard of care.


In Europe we have been working with our distributor partners to reduce the '
peaks and troughs' invariably associated with half-yearly or yearly ordering by
encouraging them to reduce stock holding and move to regular monthly standing
orders.  This process, which will help us with production planning and
manufacturing efficiency, has been welcomed by our distributors and the first
phase should be completed by the end of the first half of the year.


The Company will release the first of its DP-series of disposable probes in the
USA in July of this year, following notification of approval by the US
regulatory body, the FDA.  The DP series of probes can be placed nasally as well
as orally, allowing patients who previously could not be monitored, because of
restricted oral access to benefit from the use of the CardioQ.  This is a key
first step in the process of making our entire probe range available to
physicians in the US and this is the first new Deltex Medical probe to be
approved by the FDA since 1995.


In February we announced the acquisition of the TECO oesophageal Doppler monitor
business from Medicina Limited.  This acquisition will allow us to integrate the
best features of the TECO system into the next generation of CardioQ monitors
and further strengthen our intellectual property portfolio.  We have already
begun the process of converting the existing TECO installed base to CardioQs,
further consolidating our position in the growing market for haemodynamic
optimisation.


We have recently learned that the trial undertaken at the Freeman Hospital in
Newcastle into the use of the CardioQ in patients undergoing major bowel surgery
has been accepted for publication in the British Journal of Surgery in September
of this year.  We expect this publication to increase substantially levels of
interest in the surgical community.  We expect the results of this study to
support further the concept that hospitals and surgical teams that use the
CardioQ as a standard of care deliver the lowest mortality rates, the lowest
readmission rates and the shortest lengths of hospital stay achieved amongst
their peers.


Today we announced that we had raised a further £480,000 before expenses in new
equity capital through the placing of 2,400,000 new ordinary shares of 1p each
at 20p per share.  Application will be made for the new shares to be traded on
AIM and it is expected that dealings will commence on 9 May 2006.  Following the
issue of these new shares the Company has a total of 76,549,216 ordinary shares
in issue.  This capital will be used to fund the expansion of our sales presence
in Europe and allow us to take up an opportunity that has recently emerged to
sell directly to our customers in Switzerland and Spain.  This move will give us
greater control over the delivery of our sales message and clinical training in
these territories and will enable us to refine further our marketing approach,
based on achievements to date in our home market.


Our monthly cash burn coming into 2006 was the lowest in the Company's history.
This downward trend has continued in the first quarter of 2006 and the Board is
looking forward to moving to profitability.'




For further information, please contact:-

Deltex Medical Group plc
01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics
0207 831 3113
David Yates
John Gilbert


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.


The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.


There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works


  • proved that the CardioQ works in a wide range of surgical procedures


  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.





                      This information is provided by RNS
            The company news service from the London Stock Exchange